2-[(3-chlorophenyl)methylene]-3-oxobutanoic acid,ethyl ester | 15725-23-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-[(3-chlorophenyl)methylene]-3-oxobutanoic acid,ethyl ester
• 英文别名: 2-acetyl-3-(3-chlorophenyl)-acrylic acid ethylester；ethyl (2Z)-2-[(3-chlorophenyl)methylidene]-3-oxobutanoate
• CAS: 15725-23-2；24405-38-7；24405-37-6
• 化学式: C₁₃H₁₃ClO₃
• 分子量: 252.697
• InChiKey: XNQUEGZRSAENCP-WQLSENKSSA-N

物化性质

• 沸点：
  120-123 °C(Press: 0.1 Torr)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(3-chlorophenyl)methylene]-3-oxobutanoic acid,ethyl ester 、 methyl (Z)-3-(2-sulfanylethylamino)but-2-enoate 以 甲醇 为溶剂， 以40%的产率得到6-O-ethyl 8-O-methyl (7S,8S,8aS)-7-(3-chlorophenyl)-5,8a-dimethyl-2,3,7,8-tetrahydro-[1,3]thiazolo[3,2-a]pyridine-6,8-dicarboxylate
  参考文献：
  名称：

  Synthesis of thiazolo[3,2-a]pyridines from enaminoesters by tandem conjugate addition-cyclization

  摘要：

  Several representative compounds with the new heterocyclic system thiazolo[3,2-a]pyridine have been obtained by condensation between alpha,beta-unsaturated ketoesters and the N-mercaptoethylenamines of beta-ketoesters in a tandem conjugate addition-cyclization process. The stereochemistry of these products is different from that observed for the products obtained from related N-hydroxyethylenamines. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(97)10574-3
• 作为产物：
  描述：

  乙酰乙酸乙酯 、 3-氯苯甲醛 在 papain 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 120.0h， 生成 2-[(3-chlorophenyl)methylene]-3-oxobutanoic acid,ethyl ester 、 2-acetyl-3-(3-chlorophenyl)-acrylic acid ethylester
  参考文献：
  名称：

  酶催化混杂：木瓜蛋白酶催化的Knoevenagel反应。

  摘要：

  木瓜蛋白酶作为一种可持续且廉价的生物催化剂，首次用于在DMSO /水中催化Knoevenagel反应。各种各样的芳族，杂芳族和α，β-不饱和醛都可以与活性较低的亚甲基化合物乙酰丙酮和乙酰乙酸乙酯反应。以中等至优异的产率获得产品，Z / E选择性高达100：0。这种生物催化混杂的情况不仅扩大了木瓜蛋白酶在新化学转化中的应用，而且还可以发展成为有机合成的潜在有价值的方法。

  DOI：

  10.1016/j.biochi.2011.09.018

文献信息

• 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05202330A1

  公开（公告）日：1993-04-13

  Pyrimidine compounds of the formula ##STR1## wherein X is sulfur or oxygen, Y is R.sub.11 or --O--R.sub.1, and R.sub.4 is aryl or heterocyclo are disclosed. These compounds are useful as cardiovascular agents, particularly anti-hypertensive agents, due to their calcium entry blocking vasodilator activity.

  公开了符合以下公式的嘧啶化合物##STR1##其中X是硫或氧，Y是R.sub.11或--O--R.sub.1，R.sub.4是芳香族或杂环。这些化合物由于其钙通道阻滞血管扩张剂活性而被用作心血管药物，特别是抗高血压药物。
• A simple method for the preparation of functionalized trisubstituted alkenes and α,β,γ,δ-unsaturated carbonyl compounds by using natural amino acid l-tryptophan
  作者：Ying Hu、Yan-Hong He、Zhi Guan

  DOI：10.1016/j.catcom.2010.01.016

  日期：2010.3

  reactive acetylacetone and ethyl acetoacetate. The reactions were carried out at room temperature and gave good yields. It is a convenient entry for preparation of functionalized trisubstituted alkenes and α,β,γ,δ-unsaturated carbonyl compounds.

  伯天然氨基酸1-色氨酸首次用作脂族，芳族，杂芳族和α，β-不饱和醛与反应性较低的乙酰丙酮和乙酰乙酸乙酯的Knoevenagel缩合反应的催化剂。反应在室温下进行，并得到良好的收率。这是制备官能化的三取代烯烃和α，β，γ，δ-不饱和羰基化合物的方便方法。
• [EN] 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 4H-[1,2,4]TRIAZOLO[5,1-B]PYRIMIDIN-7-ONE À TITRE D'ANTAGONISTES DES RÉCEPTEURS CCR2B
  申请人：ASTRAZENECA AB

  公开号：WO2011114148A1

  公开（公告）日：2011-09-22

  The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical compositions, which comprise compounds that act via antagonism of the CCR2b receptor for which MCP-1 is one of the known ligands and so may be used to treat inflammatory disease, atherosclerosis, diabetes, obesity, cancer, chronic obstructive pulmonary disease (COPD) rheumatoid arthritis and/or neuropathic pain, which is mediated by these receptors.

  本发明涉及用于组合物中的新化合物，用于它们的制备过程，用于它们的制备中有用的中间体以及它们作为治疗剂的用途。本发明还涉及包含通过对CCR2b受体的拮抗作用而起作用的化合物的药物组合物，其中MCP-1是已知的配体之一，因此可用于治疗由这些受体介导的炎症性疾病、动脉粥样硬化、糖尿病、肥胖症、癌症、慢性阻塞性肺病（COPD）、类风湿性关节炎和/或由这些受体介导的神经病痛。
• Pyrazolopyridine derivatives
  申请人：Abe Yoshito

  公开号：US20060004003A1

  公开（公告）日：2006-01-05

  The invention relates to compound of the formula (I) or its salt, in which R 1 , R 2 , R 3 and R 4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

  该发明涉及式(I)的化合物或其盐，其中R1、R2、R3和R4如描述中定义，它们作为药物的用途，它们的制备过程以及用于治疗PDE-IV或TNF-α介导的疾病的用途。
• METHOD FOR PRODUCING PYRIMIDINE COMPOUND
  申请人：Takahashi Daisuke

  公开号：US20080009622A1

  公开（公告）日：2008-01-10

  Compound (II) and compound (III) are reacted to give compound (IVa) and/or compound (IVb); which are/is then reacted with compound (V) to give compound (I). wherein X is a methylthio group and the like, R 1 and R 2 are each a lower alkyl group optionally having substituent(s), an aryl group optionally having substituent(s) and the like, R 3 is a lower alkyl group, R 4 is a hydrogen atom, a lower alkyl group optionally having substituent(s) and the like, and Q is a carboxylate group and the like.

  化合物（II）和化合物（III）反应生成化合物（IVa）和/或化合物（IVb）; 然后将其与化合物（V）反应生成化合物（I）。其中X是甲基硫基等基团，R1和R2分别是较低的烷基基团，可选地具有取代基，芳基基团，可选地具有取代基等，R3是较低的烷基基团，R4是氢原子，较低的烷基基团，可选地具有取代基等，Q是羧酸盐基团等。